Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2− Advanced Breast Cancer
Tokunaga, Eriko , Park, In Hae , Huober, Jens , Stoffregen, C., Shekarriz, Sarah, Gainford, M. Corona, Price, Gregory L., Hae Park, In , Goetz, Matthew P. , Martín, Miguel , Toi, Masakazu , André, Valérie , Johnston, Stephen

Mayo Clinic

The Oncologist | June 14, 2020 | Volume: 25 | Issue: 9 | Pages: e1346-e1354

10.1634/theoncologist.2020-0084 | PMID 32536013 Get It

Abstract Background MONARCH 3, a phase III trial (NCT02246621) of postmenopausal women with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC), previously demonstrated significantly improved progression-free survival in patients receiving abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI). This study evaluated patient-reported outcomes, including global health-related quality of life (HRQoL), functioning, and symptoms. Methods Patients were randomly assigned 2:1 to receive abemaciclib (150 mg twice daily; n = 328) or placebo (n = 165), plus 1 mg anastrozole or 2.5 mg letrozole daily. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 and Breast Cancer–Specific Quality of Life Questionnaire HRQoL instruments were administered at baseline, every two cycles during cycles 2 through 19 (each cycle being 28 days), every three cycles thereafter, and once at a short-term posttherapy follow-up visit (approximately 30 days after discontinuation). Longitudinal mixed regression and Cox proportional hazards models evaluated postbaseline change and time to sustained deterioration (TTSD), respectively. Results Baseline scores were similar between treatment arms. Although select scores statistically favored the placebo arm, global HRQoL, most symptoms, and functioning scales did not meet the threshold for clinically meaningful differences between treatment arms. Only diarrhea favored the placebo arm with statistically and clinically meaningful differences. There were no TTSD differences between treatment arms for global HRQoL, most symptoms (except diarrhea), or functioning. Conclusion Over a 2-year period, there were no clinically meaningful differences in global HRQoL, functioning, and most symptoms for patients receiving abemaciclib plus NSAI compared with NSAI alone. Only diarrhea favored the placebo arm, consistent with prior safety data, which has been shown to be manageable and reversible. Combined with clinical efficacy, results support treatment with abemaciclib plus NSAI for postmenopausal women with HR+, HER2− ABC. Implications for Practice The addition of abemaciclib to a nonsteroidal aromatase inhibitor (NSAI) was not associated with a clinically meaningful detriment in patient-reported global health-related quality of life, functioning, and most symptoms in postmenopausal women with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC). Prior studies have also demonstrated clinical efficacy of abemaciclib plus NSAI compared with NSAI alone, including improved progression-free survival and objective response rate. These results also complement previously reported toxicity data, as measured by investigator-assessed adverse events. Taken together, these results support treatment with abemaciclib plus NSAI for postmenopausal women with HR+, HER2− ABC.
Effect of Bowel Preparation Volume in Inpatient Colonoscopy. Results of a Prospective, Randomized, Comparative Pilot Study
Hernandez, Patricia V. , Horsley‐Silva, Jennifer L. , Snyder, Diana L. , Baffy, Noemi, Atia, Mary A., Koepke, Laura, Lim, Elisabeth S. , Umar, Sarah B. , Islam, Sameer, Ramirez, Francisco C. , Buras, Matthew , Ruff, Kevin

Mayo Clinic

No container title available | June 14, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.2.15794/v3 Get It

Abstract Background: Inpatient status has been shown to be a predictor of poor bowel preparation for colonoscopy; however, the optimal bowel preparation regimen for hospitalized patients is unknown. Our aim was to compare the efficacy of bowel preparation volume size in hospitalized patients undergoing inpatient colonoscopy.Methods: This prospective, single blinded (endoscopist), randomized controlled trial was conducted as a pilot study at a tertiary referral medical center. Hospitalized patients undergoing inpatient colonoscopy were assigned randomly to receive a high, medium, or low-volume preparation. Data collection included colon preparation quality, based on the Boston Bowel Preparation Scale, and a questionnaire given to all subjects evaluating the ability to completely finish bowel preparation and adverse effects (unpleasant taste, nausea, and vomiting). Results: Twenty-five colonoscopies were performed in 25 subjects. Patients who received low-volume preparation averaged a higher mean total BBPS (7.4, SD 1.62), in comparison to patients who received high-volume (7.0, SD 1.41) and medium-volume prep (6.9, SD 1.55), P = 0.77. When evaluating taste a higher score meant worse taste. The low-volume group scored unpleasant taste as 0.6 (0.74), while the high-volume group gave unpleasant taste a score of 2.2 (0.97) and the medium-volume group gave a score of 2.1 (1.36), P < 0.01.Conclusion: In this pilot study we found that low-volume colon preparation may be preferred in the inpatient setting due its better rate of tolerability and comparable bowel cleanliness when compared to larger volume preparation, although we cannot overreach any definitive conclusion. Further more robust studies are required to confirm these findings.Trial registration: clinicaltrials.gov NCT01978509
Climate change perception among dermatologists: an online survey of International Society of Dermatology members
Andersen, Louise K. , Coates, Sarah J. , Enbiale, Wendemagegn , Boos, Markus D. , Dayrit, Johannes F. , Davis, Mark , Enbiale, Wendemagegne , Davis, Mark D. P.

Mayo Clinic

International Journal of Dermatology | June 12, 2020 | Volume: 59 | Issue: 9 | Pages: No page available

10.1111/ijd.14984 | PMID 32530127 Get It

Salvage Therapy With Multikinase Inhibitors and Immunotherapy in Advanced Adrenal Cortical Carcinoma
Miller, Kevin C. , Hilger, Crystal, Ryder, Mabel , Smith, Carin Y. , Jenkins, Sarah M. , Bible, Keith C. , Chintakuntlawar, Ashish V , Bancos, Irina , Smith, Carin Y , Bible, Keith C , Ryder, Mabel , Miller, Kevin C , Chintakuntlawar, Ashish V. , Bancos, Irina , Morris, John C

Mayo Clinic

Journal of the Endocrine Society | June 9, 2020 | Volume: 4 | Issue: 7 | Pages: No page available

10.1210/jendso/bvaa069 | PMID 32666013 Get It

Abstract Background Median overall survival is 12 to 15 months in patients with metastatic adrenal cortical carcinoma (ACC). Etoposide, doxorubicin, and cisplatin with or without the adrenolytic agent mitotane is considered the best first-line approach in this context, but has limited activity and no curative potential; additional salvage therapeutic options are needed. Methods Fifteen total patients with recurrent/metastatic ACC were treated with single-agent multikinase inhibitors (MKI) (n = 8), single-agent PD-1 inhibition (n = 8), or cytotoxic chemotherapy plus PD-1 inhibition (n = 4) at our institution as later-line systemic therapies in efforts to palliate disease and attempt to achieve a therapeutic response when not otherwise possible using standard approaches. Results Two of 8 patients (25%) treated with single-agent MKI achieved a partial response (PR), including 1 PR lasting 23.5 months. Another 3 patients (38%) had stable disease (SD); median progression-free survival (PFS) with single-agent MKI was 6.4 months (95% confidence interval [CI] 0.8—not reached). On the other hand, 2 of 12 patients (17%) treated with PD-1 inhibitors (either alone or in combination with cytotoxic chemotherapy) attained SD or better, with 1 patient (8%) achieving a PR; median PFS was 1.4 months (95% CI 0.6-2.7). Conclusions Our single-institution experience suggests that select ACC patients respond to late-line MKI or checkpoint inhibition despite resistance to cytotoxic agents. These treatments may be attractive to ACC patients with limited other therapeutic options. The use of MKI and immunotherapy in ACC warrants prospective investigation emphasizing parallel correlative studies to identify biomarkers that predict for response.
Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019
Kelly, William Kevin, Cheng, Heather H. , Cookson, Michael S. , Dahut, William L. , Weissman, Scott M., Soule, Howard R. , Petrylak, Daniel P. , Dicker, Adam P. , AlDubayan, Saud H. , Pettaway, Curtis A. , Daly, Mary B., Mohler, James L. , Parsons, J. Kellogg , Pilarski, Robert , Blanco, Amie , Woodson, Ashley, Taplin, Mary-Ellen, Polascik, Thomas J. , Hyatt, Colette, Feng, Felix Y. , Mullane, Michael P., Powers, Jacqueline, Concepcion, Raoul S. , Lin, Daniel W. , Wender, Richard C. , Mark, James Ryan , Costello, Anthony J. , Isaacs, William B. , Xu, Jianfeng , Weitzel, Jeffrey N. , Andriole, Gerald L. , Beltran, Himisha , Briganti, Alberto , Byrne, Lindsey , Calvaresi, Anne, Chandrasekar, Thenappan , Chen, David Y.T. , Dobi, Albert , Crawford, E. David , Eastham, James A., Eggener, Scott E. , Freedman, Matthew L. , Garnick, Marc B. , Gomella, Patrick T. , Handley, Nathan , Hurwitz, Mark , Izes, Joseph K. , Karnes, R. Jeffrey , Lallas, Costas D. , Languino, Lucia R. , Loughlin, Kevin R. , Lu‐Yao, Grace , Malkowicz, S. Bruce, Mann, Mark, Mille, Patrick , Miner, Martin , Morgan, Todd M. , Mucci, Lorelei A. , Nielsen, Sarah M. , O’Neil, Brock , Pinover, Wayne H., Pinto, Peter A. , Poage, Wendy, Raj, Ganesh V. , Ryan, Charles J. , Schiewer, Matthew J. , Szymaniak, Brittany M. , Tester, William , Trabulsi, Edouard J. , Vapiwala, Neha , Gomella, Leonard G. , Weitzel, Jeffrey N , Morgan, Todd M , Cheng, Heather H , Dicker, Adam P , Giri, Veda N. , Knudsen, Karen E. , Cooney, Kathleen A. , Toland, Amanda Ewart , Pritchard, Colin C. , Carroll, Peter R , Rahm, Alanna Kulchak , Taplin, Mary‐Ellen , Helfand, Brian T. , Morgans, Alicia K. , Burnett, Arthur L. “Bud” , Sartor, Oliver , Den, Robert B. , Loeb, Stacy , López, Ana María , Moreno, Jose, Myers, Ronald E. , Rebbeck, Timothy R. , Sandler, Howard M. , Scott, E. Michael D., Yu, Evan Y , Zeigler-Johnson, Charnita M

Mayo Clinic

Journal of Clinical Oncology | June 9, 2020 | Volume: 38 | Issue: 24 | Pages: 2798-2811

10.1200/jco.20.00046 | PMID 32516092 Get It

PURPOSE Germline testing (GT) is a central feature of prostate cancer (PCA) treatment, management, and hereditary cancer assessment. Critical needs include optimized multigene testing strategies that incorporate evolving genetic data, consistency in GT indications and management, and alternate genetic evaluation models that address the rising demand for genetic services. METHODS A multidisciplinary consensus conference that included experts, stakeholders, and national organization leaders was convened in response to current practice challenges and to develop a genetic implementation framework. Evidence review informed questions using the modified Delphi model. The final framework included criteria with strong (> 75%) agreement (Recommend) or moderate (50% to 74%) agreement (Consider). RESULTS Large germline panels and somatic testing were recommended for metastatic PCA. Reflex testing—initial testing of priority genes followed by expanded testing—was suggested for multiple scenarios. Metastatic disease or family history suggestive of hereditary PCA was recommended for GT. Additional family history and pathologic criteria garnered moderate consensus. Priority genes to test for metastatic disease treatment included BRCA2, BRCA1, and mismatch repair genes, with broader testing, such as ATM, for clinical trial eligibility. BRCA2 was recommended for active surveillance discussions. Screening starting at age 40 years or 10 years before the youngest PCA diagnosis in a family was recommended for BRCA2 carriers, with consideration in HOXB13, BRCA1, ATM, and mismatch repair carriers. Collaborative (point-of-care) evaluation models between health care and genetic providers was endorsed to address the genetic counseling shortage. The genetic evaluation framework included optimal pretest informed consent, post-test discussion, cascade testing, and technology-based approaches. CONCLUSION This multidisciplinary, consensus-driven PCA genetic implementation framework provides novel guidance to clinicians and patients tailored to the precision era. Multiple research, education, and policy needs remain of importance.
Creation of a New Educational Podcast: “Headmirror’s ENT in a Nutshell”
Barnes, Jason H. , Smith, Alyssa J. , Kiessling, Patrick , Marinelli, John P. , Carlson, Matthew L. , Choby, Garret , Bowe, Sarah N.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | June 9, 2020 | Volume: 163 | Issue: 4 | Pages: 623-625

10.1177/0194599820930662 | PMID 32513092 Get It

Podcasts are online digital audio programs that are disseminated via online subscription that are easily accessible through computers or smartphones. Increasingly, residents and medical students are prioritizing podcasts for asynchronous medical education due to ease of use, convenience (eg, use while exercising or commuting), and repeatability. Some trainees have found podcasts more useful than traditional didactic lectures. Given the increasing requirements of social distancing and the need for distance medical education platforms, podcast production can serve as a useful tool to complement resident and medical student education and is a resource that will remain accessible in perpetuity. An otolaryngology specialty podcast, “Headmirror’s ENT in a Nutshell,” was created to augment asynchronous learning and address the acute need for distance learning opportunities. Over the first 7 weeks of production, 50 episodes were created. Episodes were posted on www.headmirror.com, with subscription services available through Apple Podcast, Spotify, and other platforms.
Breast Cancer in the Young Patient: Review of Therapy and Treatment Considerations
Subhedar, Preeti , McLaughlin, Sarah A.

Mayo Clinic

Breast Cancer Management | June 8, 2020 | Volume: 9 | Issue: 2 | Pages: No page available

10.2217/bmt-2020-0008 Get It

NCCN Guidelines Insights: Cervical Cancer, Version 1.2020
Abu‐Rustum, Nadeem R. , Yashar, Catheryn M. , Bean, Sarah , Bradley, Kristin , Campos, Susana M. , Chon, Hye Sook, Damast, Shari , Fisher, Christine M. , Frederick, Peter J., Gaffney, David K. , Giuntoli, Robert , Han, Ernest , Huh, Warner K. , Lurain, John R., Mariani, Andrea , Nagel, Christa , Nekhlyudov, Larissa , Fader, Amanda N. , Remmenga, Steven W., Reynolds, R. Kevin, Sisodia, Rachel , Tillmanns, Todd , Ueda, Stefanie , Urban, Renata R. , Wyse, Emily , McMillian, Nicole R., Motter, Angela D., Chu, Christina , Cohn, David E. , Crispens, Marta Ann , Mutch, David G.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | June 5, 2020 | Volume: 18 | Issue: 6 | Pages: 660-666

10.6004/jnccn.2020.0027 | PMID 32502976 Get It

The NCCN Guidelines for Cervical Cancer provide recommendations for diagnostic workup, staging, and treatment of patients with the disease. These NCCN Guidelines Insights focus on recent updates to the guidelines, including changes to first- and second-line systemic therapy recommendations for patients with recurrent or metastatic disease, and emerging evidence on a new histopathologic classification system for HPV-related endocervical adenocarcinoma.
“Slowed Down but Not Stopped”: A Spiritual Life Review Intervention in Patients with Neurodegenerative Disease
Sytsma, Terin T. , Bjork, Lori B., Jenkins, Sarah M. , Chatterjee, Krishanu , Piderman, Katherine M.

Mayo Clinic

Journal of Pastoral Care & Counseling: Advancing theory and professional practice through scholarly and reflective publicati | June 4, 2020 | Volume: 74 | Issue: 2 | Pages: 108-114

10.1177/1542305020913054 | PMID 32496953 Get It

Spiritual health is important in managing and coping with chronic and debilitating illnesses, such as neurodegenerative diseases. However, few spiritual interventions have addressed this population. This article quantitatively and qualitatively evaluates outcomes of a spiritual life review in neurodegenerative diseases patients. The majority of participants improved or maintained quality of life and spiritual/emotional well-being following the intervention. Spiritual life review may be an important intervention in the comprehensive care of patients with neurodegenerative diseases.
Electroconvulsive Therapy in Pregnancy: Safety, Best Practices, and Barriers to Care
Rose, Sherrill “Charlie”, Kuller, Jeffrey A., Rose, Sherrill, Dotters-Katz, Sarah Kathleen

Mayo Clinic

Obstetrical & Gynecological Survey | June 2, 2020 | Volume: 75 | Issue: 3 | Pages: 199-203

10.1097/ogx.0000000000000763 | PMID 32232498 Get It

Importance Approximately 10% to 16% of women meet diagnostic criteria for depression during pregnancy. Untreated maternal depression is associated with adverse pregnancy outcomes including premature birth, low birth weight, and fetal growth restriction. Objective The aim of this study is to review the current safety data on electroconvulsive therapy (ECT) in pregnancy and provide guidance to clinicians on the role of ECT in pregnancy and the special considerations for its use in our population. Evidence Acquisition We reviewed 4 meta-analyses on the use of ECT in pregnancy as well as the source material (case series, etc) for these meta-analyses. We reviewed the official position statements on ECT in pregnancy from obstetric and psychiatric governing bodies as well as clinical best practice information from practitioners of ECT in pregnancy. Results Electroconvulsive therapy may be underutilized due to stigma and lack of access for these women. Rates of ECT use in pregnancy are difficult to determine. There are physiologic differences in pregnancy that merit additional attention during ECT, including increased risk of aspiration, concern for aortocaval compression, and the possibility of fetal heart rate changes associated with prolonged seizure activity. Serious adverse outcomes associated with ECT use in pregnancy are rare. Conclusions and Relevance Electroconvulsive therapy is a highly effective and safe treatment modality for unipolar depression, bipolar disorder, schizophrenia, and other psychiatric illnesses. Electroconvulsive therapy treatment in pregnancy requires a multidisciplinary team approach with obstetrics, maternal-fetal medicine, psychiatry, and anesthesiology, but is overall felt to be safe and effective. Target Audience Obstetricians and gynecologist, family medicine physicians. Learning Objectives After completing this activity, the learner should be better able to assess the current evidence and best practices regarding ECT use in pregnant patients; describe risks, benefits, and contraindications to ECT use in pregnant patients; and explain the potential for practice gaps in the utilization of ECT in pregnancy.